Where sermorelin stands
Sermorelin is a 29-amino-acid peptide analog of growth-hormone-releasing hormone (GHRH). Unlike many of the newer "research peptides," sermorelin has an FDA-approved drug history: it was marketed as Geref beginning in the 1990s for pediatric growth-hormone deficiency. The branded products were eventually discontinued for commercial reasons — not safety reasons — and sermorelin moved into the compounding pharmacy world, where it's been prescribed off-label for adult use ever since.
For California patients, this regulatory history matters. Sermorelin's pathway under section 503A is clearer than newer peptides like BPC-157 because it sits on a more developed pharmacological record.
| Question | Answer for California residents |
|---|---|
| Is sermorelin a controlled substance? | No |
| Was sermorelin ever FDA-approved? | Yes — historically as Geref |
| Is it currently compounded under 503A? | Yes, by many U.S. pharmacies |
| Does California have a sermorelin-specific ban? | No |
| Does it require an in-state licensed physician? | Yes — telehealth across states works through state licensure |
From Geref to compounded
Geref (sermorelin acetate) was approved by FDA in the 1990s for the diagnosis and treatment of pediatric growth-hormone deficiency. The branded versions were withdrawn from the U.S. market — Geref Diagnostic and Geref injection — but the active ingredient remained well-characterized, with established pharmacokinetics, dosing ranges, and safety profile. That history is why sermorelin sits comfortably in the compounded-medication world today.
503A pharmacies can compound sermorelin under prescription for an individual patient. It's a typical "growth-hormone-releasing peptide" used in adult longevity and sleep-quality contexts, often paired with a secretagogue like ipamorelin. For more on the comparison, see sermorelin vs. CJC-1295 + ipamorelin.
Sermorelin's regulatory tail — FDA approval as Geref — makes its compounding pathway clearer than most newer peptides, in California as elsewhere.
Prescribing in California
California follows the federal 503A framework on sermorelin. There is no state-level sermorelin ban or special restriction. The state-specific layer is licensure: a physician prescribing for a California patient must hold an active California medical license, and the dispensing pharmacy must be properly registered to ship into the state.
Among the peptides Boswell offers, sermorelin is one of the more straightforward to prescribe and supply, precisely because of its longer regulatory tail.
How Boswell handles California
For a California resident, the Boswell flow is: virtual intake with a California-licensed physician, evaluation of fit, and — if appropriate — a sermorelin prescription compounded by a 503A pharmacy and shipped to the patient. The sermorelin product page details the protocol; how it works walks through the broader sequence.
Questions worth asking your provider
- Are you a physician licensed in my state?
- Is the dispensing pharmacy a 503A compounding pharmacy registered to ship into my state?
- What dosing protocol are you considering, and how is it titrated?
- Are there reasons this peptide wouldn't be appropriate for me?
- How does refill review work — who follows up, and when?
Sources